Go back

Servier backs Monash in pharma deal

Medical scientists at Monash have secured backing from French pharmaceutical giant Le Laboratoires Servier for a drug research programme, the university announced on 30 January.

The Monash Institute of Pharmaceutical Sciences will collaborate with the French company on drug discovery and research on G Protein Coupled Receptors (GPCRs), which is the largest drug target family in the human genome.

Under the agreement, Servier will provide annual payments for research activities and fund up to 15 scientists working exclusively on collaborative projects.

The collaboration will run for an initial three years and cover potential therapeutic fields including metabolism, cardiology, neurology and psychiatry, rheumatology and oncology.